US · LNTH
Lantheus Holdings, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Bedford, MA 01862
- Website
- lantheus.com
Price · as of 2025-12-31
$85.50
Market cap 5.09B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $104.64 | +22.39% |
| Intrinsic Value(DCF) | $93.35 | +9.18% |
| Graham-Dodd Method(GD) | $29.90 | -65.03% |
| Graham Formula(GF) | $30.12 | -64.77% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $2.13 | $18.77 | $0.00 | $0.00 | $0.00 |
| 2016 | $13.25 | $37.06 | $0.00 | $0.36 | $9.03 |
| 2017 | $16.00 | $44.98 | $0.00 | $16.75 | $57.94 |
| 2018 | $23.45 | $46.89 | $0.38 | $6.75 | $12.27 |
| 2019 | $15.07 | $39.73 | $2.00 | $6.60 | $7.54 |
| 2020 | $19.65 | $37.60 | $2.00 | $7.17 | $0.00 |
| 2021 | $51.82 | $39.91 | $0.00 | $0.69 | $0.00 |
| 2022 | $71.26 | $85.95 | $12,682.03 | $7.68 | $50.37 |
| 2023 | $62.52 | $104.49 | $17,130.58 | $34.98 | $215.58 |
| 2024 | $106.34 | $143.19 | $7,060.52 | $37.41 | $116.18 |
| 2025 | $76.30 | $104.64 | $385.95 | $29.90 | $30.12 |
AI valuation
Our deep-learning model estimates Lantheus Holdings, Inc.'s (LNTH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $104.64
- Current price
- $85.50
- AI upside
- +22.39%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$93.35
+9.18% upside
Graham-Dodd
$29.90
-65.03% upside
Graham Formula
$30.12
-64.77% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LNTH | Lantheus Holdings, Inc. | $85.50 | 5.09B | +22% | +9% | -65% | -65% | 22.05 | 4.73 | 3.34 | 14.36 | — | 40.39 | 61.10% | 20.16% | 15.15% | 21.45% | 30.32% | 11.10% | 0.00 | 15.74 | 2.70 | 2.15 | -1.07 | -2179.00% | 50.00% | -2820.00% | 6.88% | 1.17 | 46.40% | 0.00% | 0.00% | 1.26% | 15.41 | 13.53 | 3.11 | 4.60 |
| ACAD | ACADIA Pharmaceuticals In… | $24.56 | 4.16B | +74% | +42% | -54% | +114% | 12.85 | 3.97 | 3.04 | 22.02 | — | 4.75 | 91.46% | 24.10% | 23.64% | 38.89% | 513.41% | 23.39% | 0.07 | — | 2.38 | 2.18 | -2.67 | -46757.00% | 3185.00% | -77327.00% | 5.40% | 0.40 | 398.52% | 0.00% | 0.00% | 4.68% | 9.56 | 14.03 | 2.30 | 3.24 |
| ADMA | ADMA Biologics, Inc. | $15.57 | 3.71B | +161% | +134% | -67% | +6% | 26.89 | 8.28 | 7.74 | 19.93 | — | 8.35 | 57.39% | 37.53% | 28.80% | 35.56% | 38.62% | 26.40% | 0.17 | 26.93 | 6.71 | 3.54 | -0.04 | -2593.00% | 1963.00% | -7473.00% | 0.70% | 0.72 | 6.98% | 0.00% | 0.00% | 0.81% | 20.60 | 141.74 | 7.73 | 18.36 |
| AMRX | Amneal Pharmaceuticals, I… | $13.81 | 4.34B | +181% | -25% | -85% | -74% | 59.88 | 4.86 | 1.43 | -793.31 | — | -15.90 | 36.88% | 14.02% | 2.39% | 18.52% | 25.08% | 2.01% | 0.14 | 1.75 | 2.17 | 1.34 | 30.17 | -15789.00% | 805.00% | 2263.00% | 6.26% | 0.39 | 17.41% | 0.00% | 0.00% | 61.20% | 9.83 | 15.40 | 1.38 | 2.26 |
| BHC | Bausch Health Companies I… | $5.93 | 2.2B | +958% | +67% | — | +6% | 18.37 | -3.99 | 0.21 | 7.14 | — | -0.13 | 68.33% | 20.07% | 1.51% | -13.10% | 4.28% | 0.45% | -38.35 | 1.37 | 1.47 | 0.88 | 6.42 | -41538.00% | 711.00% | -2040.00% | 45.49% | 0.34 | 5.18% | 0.00% | 0.00% | 34.48% | 10.68 | 22.02 | 2.14 | 0.28 |
| CRNX | Crinetics Pharmaceuticals… | $41.10 | 4.21B | +36% | -54% | — | — | -8.22 | 3.86 | 705.95 | -6.17 | -24.08 | 3.86 | 80.15% | -9534.48% | -8585.18% | -40.17% | -2936.77% | -36.34% | 0.05 | — | 12.32 | 12.09 | 0.11 | 3415.00% | 42166.00% | 6695.00% | -10.03% | -4.44 | -2180.46% | 0.00% | 0.00% | 0.00% | -5.51 | -7.42 | 525.26 | 14.87 |
| HCM | HUTCHMED (China) Limited | $14.33 | 2.59B | +159% | -38% | -61% | — | 74.95 | 3.72 | 4.49 | 147.56 | — | 3.74 | 44.64% | -6.94% | 5.99% | 5.06% | 131.28% | 2.95% | 0.12 | -15.22 | 2.83 | 2.67 | -4.55 | -6333.00% | -2480.00% | -10934.00% | -0.62% | 0.00 | 62.24% | 0.00% | 0.00% | 1.28% | -47.63 | -119.38 | 3.30 | 3.49 |
| HNGE | Hinge Health, Inc. | $42.76 | 3.37B | +11% | +616% | — | — | -6.72 | 9.38 | 6.04 | -5.91 | -0.20 | 11.39 | 79.65% | -92.94% | -89.86% | -132.86% | 6793.55% | -74.51% | 0.02 | — | 1.47 | 1.19 | 0.37 | 336000.00% | 5058.00% | 27749.00% | 4.81% | 0.47 | -2122.88% | 0.00% | 0.00% | 1.83% | -5.85 | 18.72 | 5.44 | 2.49 |
| INDV | Indivior Pharmaceuticals … | $32.72 | 4.08B | +249% | +42% | -77% | -38% | 19.04 | -40.38 | 3.23 | 12.71 | 0.18 | -39.58 | 80.23% | 21.15% | 16.95% | -93.96% | -87.53% | 16.67% | -0.62 | 5.82 | 0.71 | 0.49 | -0.44 | 1083333.00% | 429.00% | -142857.00% | -2.33% | -0.03 | 35.36% | 0.00% | 0.00% | 5.03% | 14.75 | -41.54 | 3.12 | 3.05 |
| PRAX | Praxis Precision Medicine… | $336.75 | 7.12B | -61% | — | — | — | -24.53 | 8.47 | — | -22.57 | -76.60 | 8.47 | 0.00% | — | — | -45.83% | -195.82% | -42.68% | 0.00 | — | 10.22 | 10.03 | 1.18 | 3203.00% | -10000.00% | 8908.00% | -3.35% | -4.17 | -149.55% | 0.00% | 0.00% | 1.92% | -20.97 | -27.46 | — | 72.54 |
| SUPN | Supernus Pharmaceuticals,… | $54.73 | 3.14B | +101% | -41% | -57% | -59% | 23.92 | 1.71 | 2.67 | 7.56 | 0.44 | 4.45 | 88.23% | 12.34% | 11.16% | 7.55% | 9.31% | 5.58% | 0.03 | — | 2.35 | 2.04 | -0.20 | 546962.00% | 894.00% | 5491.00% | 9.69% | 0.59 | 25.85% | 0.00% | 0.00% | 0.09% | 16.50 | 7.87 | 2.04 | 4.79 |
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
- CEO
- Mary Anne Heino
- Employees
- 808
- Beta
- -0.08
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($93.35 ÷ $85.50) − 1 = +9.18% (DCF, example).